Corifollitropin Alfa Combined With Menotropin Versus Follitropin and Lutropin Alfa in Expected Suboptimal Responders
Status:
Completed
Trial end date:
2019-09-10
Target enrollment:
Participant gender:
Summary
In an opened randomized study of women undergoing in vitro fertilization with expected
suboptimal response to controlled ovarian stimulation (Poseidon Group 2b) investigators will
examine clinical efficacy and safety of two stimulation protocols: Corifollitropin alfa
(Elonva) in combination with menotropin (Merional) versus Follitropin alfa and lutropin alfa
(Pergoveris).
Phase:
Phase 4
Details
Lead Sponsor:
D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology